ImmunityBio, Inc., a clinical-stage immunotherapy company, appointed Enrique Diloné, Ph.D., chief technology officer. With more than three decades of pharmaceutical manufacturing expertise, Diloné will assume responsibility for all global manufacturing functions as the company prepares for potential FDA approval of a key bladder cancer drug. He will report directly to president and CEO Richard Adcock.

Diloné’s career spans more than 30 years of chemistry, manufacturing, and controls (CMC) management, pharmaceutical supply chain management, and regulatory responsibilities. During his professional tenure, he has contributed to the licensure of several commercial products including Galafold, ZolpiMist and MACUGEN, and to the development and manufacture of several more clinical products.

He will work on developing and managing ImmunityBio’s worldwide manufacturing capacity, both company owned and contract, along with responsibility for quality assurance, quality control, manufacturing operations, supply chain and project management.

“Enrique joins us at an exciting and important time in ImmunityBio’s journey, at a time when we have multiple Phase 2 and 3 trials underway for therapeutics and vaccines, ready-to-scale manufacturing, and we continue to work diligently to get our drug approved for non-muscle invasive bladder cancer,” said Richard Adcock, President, and CEO of ImmunityBio. “Enrique will play a critical role in helping us manage future growth through best-in-class manufacturing processes and supply chain and quality assurance processes that are second to none.”